Safety profile of meropenem: An updated review of over 6000 patients treated with meropenem

Drug Safety

Volumn 30, Issue 8, 2007, Pages 657-668

  Linden, Peter ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CILASTATIN PLUS IMIPENEM; CLINDAMYCIN; ERTAPENEM; IMIPENEM; MEROPENEM;

ABDOMINAL INFECTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTEREMIA; BACTERIAL INFECTION; BACTERIAL MENINGITIS; BONE INFECTION; CHILDHOOD DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSTIPATION; CREATININE BLOOD LEVEL; DIARRHEA; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; EOSINOPHILIA; FEBRILE NEUTROPENIA; GASTROINTESTINAL TRACT; GLOSSITIS; GYNECOLOGIC INFECTION; HUMAN; HYPERBILIRUBINEMIA; HYPOKALEMIA; HYPOPROTEINEMIA; HYPOTENSION; INFECTIOUS ARTHRITIS; INJECTION SITE REACTION; KIDNEY FAILURE; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTOSIS; LOWER RESPIRATORY TRACT INFECTION; LUNG INFECTION; MORTALITY; NAUSEA AND VOMITING; PAIN; PATIENT MONITORING; PRIORITY JOURNAL; PROTHROMBIN TIME; PRURITUS; REVIEW; SEIZURE; SEPSIS; SEPTICEMIA; SIDE EFFECT; SKIN INFECTION; SKIN STRUCTURE; THROMBOCYTOPENIA; THROMBOCYTOSIS; THRUSH; TREATMENT INDICATION; UREA NITROGEN BLOOD LEVEL; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CLINICAL TRIALS; HUMANS; THIENAMYCINS;

EID: 34548067657     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200730080-00002     Document Type: Review

References (49)

1. Masterton RG, Turner PJ. Trends in antimicrobial susceptibility in UK centres: the MYSTIC Programme (1997-2002). Int J Antimicrob Agents 2006; 27 (1): 69-72
2. Rhomberg PR, Jones RN. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005). Diagn Microbiol Infect Dis 2007; 57 (2): 207-15
3. Goossens H, Grabein B. Prevalence and antimicrobial susceptibility data for extended-spectrum beta-lactamase- and AmpC-producing Enterobacteriaceae from the MYSTIC Program in Europe and the United States (1997-2004). Diagn Microbiol Infect Dis 2005; 53 (4): 257-64
4. Jones RN, Mendes C, Turner PJ, et al. An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: 1997-2004. Diagn Microbiol Infect Dis 2005; 53 (4): 247-56
5. Unal S, Garcia-Rodriguez JA. Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002-2004. Diagn Microbiol Infect Dis 2005; 53 (4): 265-71
6. Prescribing information for Primaxin® (Imipenem/cilastatin). Whitehouse Station (NJ): Merck & Co., Inc., 2006 Oct [online]. Available from URL: http://www.merck.com/product/usa/pi_circulars/p/primaxin/ primaxin_iv_pi.pdf [Accessed 2007 Jul 18]
7. Prescribing information for Merrem® (meropenem). Wilmington (DE): AstraZeneca [online]. Available from URL: http://www.astrazeneca-us.com/pi/ MerremIV.pdf [Accessed 2007 Jul 18]
8. Prescribing information for Invanz® (ertapenem). Whitehouse Station (NJ): Merck & Co., Inc., 2007 Mar [online]. Available from URL: http://www.merck.com/product/usa/pi_circulars/i/invanz/invanz_pi.pdf [Accessed 2007 Jul 18]
9. Lowe MN, Lamb HM. Meropenem: an updated review of its use in the management of intra-abdominal infections. Drugs 2000; 60 (3): 619-46
10. Norrby SR, Gildon KM. Safety profile of meropenem: a review of nearly 5,000 patients treated with meropenem. Scand J Infect Dis 1999; 31 (1): 3-10
11. Norrby SR, Newell PA, Faulkner KL, et al. Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem. J Antimicrob Chemother 1995; 36 Suppl. A: 207-23
12. Balfour JA, Bryson HM, Brogden RN. Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections. Drugs 1996; 51 (1): 99-136
13. Calandra GB, Wang C, Aziz M, et al. The safety profile of imipenem/cilastatin: worldwide clinical experience based on 3470 patients. J Antimicrob Chemother 1986; 18 Suppl. E: 193-202
14. Curran M, Simpson D, Perry C. Ertapenem: a review of its use in the management of bacterial infections. Drugs 2003; 63 (17): 1855-78
15. Calandra G, Lydick E, Carrigan J, et al. Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin. Am J Med 1988; 84 (5): 911-8
16. Norrby SR, Vandercam B, Louie T, et al. Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multi-clinic study. Scand J Infect Dis Suppl 1987; 52: 65-78
17. Wang C, Calandra GB, Aziz MA, et al. Efficacy and safety of imipenem/cilastatin: a review of worldwide clinical experience. Rev Infect Dis 1985; 7 Suppl. 3: S528-36
18. Harrison MP, Haworth SJ, Moss SR, et al. The disposition and metabolic fate of 14C-meropenem in man. Xenobiotica 1993 Nov; 23: 1311-23
19. Majumdar AK, Musson DG, Birk KL, et al. Pharmacokinetics of ertapeneme in healthy young volunteers. Antimicrob Agents Chemother 2002 Nov; 46 (11): 3506-11
20. Edwards SJ, Emmas CE, Campbell HE. Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infections. Curr Med Res Opin 2005; 21 (5): 785-94
21. Paul M, Yahav D, Fraser A, et al. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2006; 57 (2): 176-89
22. Bradley JS, Behrendt CE, Arrieta AC, et al. Convalescent phase outpatient parenteral antiinfective therapy for children with complicated appendicitis. Pediatr Infect Dis J 2001; 20 (1): 19-24
23. Fabian TC, File TM, Embil JM, et al. Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study. Surg Infect (Larchmt) 2005; 6 (3): 269-82
24. Hou F, Li J, Wu G, et al. A randomized, controlled clinical trial on meropenem versus imipenem/cilastatin for the treatment of bacterial infections. Chin Med J (Engl) 2002; 115 (12): 1849-54
25. Hsu HL, Lu CY, Tseng HY, et al. Empirical monotherapy with meropenem in serious bacterial infections in children. J Microbiol Immunol Infect 2001; 34 (4): 275-80
26. Snedden S, Rudoy R, Arrieta A, et al. Meropenem versus cefotaxime-based therapy for the initial treatment of infants and children hospitalised with non-CNS infections. Clin Drug Investig 1999; 17 (1): 9-20
27. Verwaest C. Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit. Clin Microbiol Infect 2000; 6 (6): 294-302
28. Zanetti G, Harbarth SJ, Trampuz A, et al. Meropenem (1.5 g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe intra-abdominal infections. Int J Antimicrob Agents 1999; 11 (2): 107-13
29. Odio CM, Puig JR, Feris JM, et al. Prospective, randomized, investigator-blinded study of the efficacy and safety of meropenem vs. cefotaxime therapy in bacterial meningitis in children. Pediatr Infect Dis J 1999; 18 (7): 581-90
30. Embil JM, Soto NE, Melnick DA. A post hoc subgroup analysis of meropenem versus imipenem/cilastatin in a multicenter, double-blind, randomized study of complicated skin and skin-structure infections in patients with diabetes mellitus. Clin Ther 2006; 28 (8): 1164-74
31. Eng RH, Munsif AN, Yangco BG, et al. Seizure propensity with imipenem. Arch Intern Med 1989; 149 (8): 1881-3
32. Wong VK, Wright Jr HT, Ross LA, et al. Imipenem/cilastatin treatment of bacterial meningitis in children. Pediatr Infect Dis J 1991; 10 (2): 122-5
33. Poutanen SM, Simor AE. Clostridium difficile-associated diarrhea in adults. CMAJ 2004; 171 (1): 51-8
34. Wistrom J, Norrby SR, Myhre EB, et al. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. J Antimicrob Chemother 2001; 47 (1): 43-50
35. Thomas C, Stevenson M, Riley TV. Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review. J Antimicrob Chemother 2003; 51 (6): 1339-50
36. Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005; 40 (11): 1586-90
37. Hurst M, Lamb HM. Meropenem: a review of its use in patients in intensive care. Drugs 2000; 59 (3): 653-80
38. Alvarez C, Ramos JM, San Juan R, et al. Risk of superinfection related to antibiotic use: are all antibiotics the same? [in Spanish]. Rev Esp Quimioter 2005; 18 (1): 39-44
39. Bourgault AM, Lamothe F, Loo VG, et al. In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in Southern Quebec, Canada. Antimicrob Agents Chemother 2006; 50 (10): 3473-5
40. Saxon A, Adelman DC, Patel A, et al. Imipenem cross-reactivity with penicillin in humans. J Allergy Clin Immunol 1988; 82 (2): 213-7
41. Prescott Jr WA, Kusmierski KA. Clinical importance of carbapenem hypersensitivity in patients with self-reported and documented penicillin allergy. Pharmacotherapy 2007; 27 (1): 137-42
42. Cunha BA. Meropenem in elderly and renally impaired patients [published erratum appears in Int J Antimicrob Agents 1999; 11 (2): 167-77]. Int J Antimicrob Agents 1998; 10 (2): 107-17
43. Fudio S, Carcas A, Pinana E, et al. Epileptic seizures caused by low valproic acid levels from an interaction with meropenem. J Clin Pharm Ther 2006; 31 (4): 393-6
44. Clause D, Decleire PY, Vanbinst R, et al. Pharmacokinetic interaction between valproic acid and meropenem. Intensive Care Med 2005; 31 (9): 1293-4
45. Coves-Orts FJ, Borras-Blasco J, Navarro-Ruiz A, et al. Acute seizures due to a probable interaction between valproic acid and meropenem. Ann Pharmacother 2005; 39 (3): 533-7
46. De Turck BJ, Diltoer MW, Cornelis PJ, et al. Lowering of plasma valproic acid concentrations during concomitant therapy with meropenem and amikacin. J Antimicrob Chemother 1998; 42 (4): 563-4
47. Santucci M, Parmeggiani A, Riva R. Seizure worsening caused by decreased serum valproate during meropenem therapy. J Child Neurol 2005; 20 (5): 456-7
48. Nagai K, Shimizu T, Togo A, et al. Decrease in serum levels of valproic acid during treatment with a new carbapenem, panipenem/betamipron. J Antimicrob Chemother 1997; 39 (2): 295-6
49. Yamagata T, Momoi MY, Murai K, et al. Panipenem-betamipron and decreases in serum valproic acid concentration. Ther Drug Monit 1998; 20 (4): 396-400